Related Experiment Video
Updated: Dec 5, 2025

A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
Practical Considerations for the Management of Cushing's Disease and COVID-19: A Case Report
Federica Beretta1, Francesca Dassie1, Matteo Parolin1
1Clinica Medica 3, Department of Medicine, University of Padua, Padua, Italy.
Insights
COVID-19 infection can cause adrenal insufficiency in Cushing's disease (CD) patients, requiring prompt treatment. Adjusting CD medications during COVID-19 is crucial for managing this complex interaction.
Area of Science:
- Endocrinology
- Infectious Diseases
- Internal Medicine
Background:
- The COVID-19 pandemic presents unique challenges for patients with complex endocrine disorders.
- Cushing's disease (CD) involves hormonal imbalances that can complicate management during acute infections.
Observation:
- A 67-year-old male with CD developed adrenal insufficiency during COVID-19 pneumonia.
- Management required dose adjustments of CD medications (pasireotide, metyrapone) and hydrocortisone therapy.
- Potential drug interactions and complications like hyperkalemia were noted.
Findings:
- COVID-19 infection can precipitate or exacerbate adrenal insufficiency in CD patients.
- Medical therapies for Cushing's syndrome may need titration or temporary cessation during COVID-19.
- Hyperkalemia in patients on heparin warrants consideration of aldosterone suppression.
Implications:
- Prompt recognition and management of adrenal insufficiency are vital in CD patients with COVID-19.
- Careful consideration of medication interactions between CD treatments and COVID-19 therapies is essential.
- Clinical vigilance for complications such as hyperkalemia can indicate underlying hormonal shifts.
Abstract:
Introduction: Italy, since the end of February 2020, is experiencing the corona virus disease 2019 (COVID-19) pandemic that may present as an acute respiratory infection. We report on COVID-19 pneumonia in the context of a complex case of Cushing's disease (CD). Case Report: A 67-year-old man with CD, who was admitted to our hospital, presented with signs and symptoms of adrenal insufficiency with persistent hypotension and glycemia toward the lower limits. We progressively withdrew almost all treatments for diabetes and CD (pasireotide and metyrapone), and i.v. hydrocortisone was necessary. A tendency to hyperkalemia was probably associated to enoxaparin. We summarized the many possible interactions between medications of Cushing's syndrome (CS) and COVID-19. Conclusion: Adrenal insufficiency might be a clinical challenge that needs a prompt treatment also in CS patients during COVID-19 infection. We should consider the possibility to titrate or temporary halt medical therapies of CS in the context of COVID-19 infection. Unexpected hyperkalemia in CS patients under treatment with heparin might be the signal of aldosterone suppression.
More Related Videos
Related Concept Videos
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
COPD: Management Using Bronchodilators and Corticosteroids
Cystic Fibrosis: Management
Sinus disease and chronic...
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Acute Pancreatitis II: Clinical Manifestations and Management
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment

